You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 196081 - 196090 of 201422 results
 
  • Record 1 TO 1000
  • Record 1001 TO 2000
  • Record 2001 TO 3000
  • Record 3001 TO 4000
  • Record 4001 TO 5000
  • Record 5001 TO 6000
  • Record 6001 TO 7000
  • Record 7001 TO 8000
  • Record 8001 TO 9000
  • Record 9001 TO 10000
  • Record 10001 TO 11000
  • Record 11001 TO 12000
  • Record 12001 TO 13000
  • Record 13001 TO 14000
  • Record 14001 TO 15000
  • Record 15001 TO 16000
  • Record 16001 TO 17000
  • Record 17001 TO 18000
  • Record 18001 TO 19000
  • Record 19001 TO 20000
  • Record 20001 TO 21000
  • Record 21001 TO 22000
  • Record 22001 TO 23000
  • Record 23001 TO 24000
  • Record 24001 TO 25000
  • Record 25001 TO 26000
  • Record 26001 TO 27000
  • Record 27001 TO 28000
  • Record 28001 TO 29000
  • Record 29001 TO 30000
  • Record 30001 TO 31000
  • Record 31001 TO 32000
  • Record 32001 TO 33000
  • Record 33001 TO 34000
  • Record 34001 TO 35000
  • Record 35001 TO 36000
  • Record 36001 TO 37000
  • Record 37001 TO 38000
  • Record 38001 TO 39000
  • Record 39001 TO 40000
  • Record 40001 TO 41000
  • Record 41001 TO 42000
  • Record 42001 TO 43000
  • Record 43001 TO 44000
  • Record 44001 TO 45000
  • Record 45001 TO 46000
  • Record 46001 TO 47000
  • Record 47001 TO 48000
  • Record 48001 TO 49000
  • Record 49001 TO 50000
  • Record 50001 TO 51000
  • Record 51001 TO 52000
  • Record 52001 TO 53000
  • Record 53001 TO 54000
  • Record 54001 TO 55000
  • Record 55001 TO 56000
  • Record 56001 TO 57000
  • Record 57001 TO 58000
  • Record 58001 TO 59000
  • Record 59001 TO 60000
  • Record 60001 TO 61000
  • Record 61001 TO 62000
  • Record 62001 TO 63000
  • Record 63001 TO 64000
  • Record 64001 TO 65000
  • Record 65001 TO 66000
  • Record 66001 TO 67000
  • Record 67001 TO 68000
  • Record 68001 TO 69000
  • Record 69001 TO 70000
  • Record 70001 TO 71000
  • Record 71001 TO 72000
  • Record 72001 TO 73000
  • Record 73001 TO 74000
  • Record 74001 TO 75000
  • Record 75001 TO 76000
  • Record 76001 TO 77000
  • Record 77001 TO 78000
  • Record 78001 TO 79000
  • Record 79001 TO 80000
  • Record 80001 TO 81000
  • Record 81001 TO 82000
  • Record 82001 TO 83000
  • Record 83001 TO 84000
  • Record 84001 TO 85000
  • Record 85001 TO 86000
  • Record 86001 TO 87000
  • Record 87001 TO 88000
  • Record 88001 TO 89000
  • Record 89001 TO 90000
  • Record 90001 TO 91000
  • Record 91001 TO 92000
  • Record 92001 TO 93000
  • Record 93001 TO 94000
  • Record 94001 TO 95000
  • Record 95001 TO 96000
  • Record 96001 TO 97000
  • Record 97001 TO 98000
  • Record 98001 TO 99000
  • Record 99001 TO 100000
  • Record 100001 TO 101000
  • Record 101001 TO 102000
  • Record 102001 TO 103000
  • Record 103001 TO 104000
  • Record 104001 TO 105000
  • Record 105001 TO 106000
  • Record 106001 TO 107000
  • Record 107001 TO 108000
  • Record 108001 TO 109000
  • Record 109001 TO 110000
  • Record 110001 TO 111000
  • Record 111001 TO 112000
  • Record 112001 TO 113000
  • Record 113001 TO 114000
  • Record 114001 TO 115000
  • Record 115001 TO 116000
  • Record 116001 TO 117000
  • Record 117001 TO 118000
  • Record 118001 TO 119000
  • Record 119001 TO 120000
  • Record 120001 TO 121000
  • Record 121001 TO 122000
  • Record 122001 TO 123000
  • Record 123001 TO 124000
  • Record 124001 TO 125000
  • Record 125001 TO 126000
  • Record 126001 TO 127000
  • Record 127001 TO 128000
  • Record 128001 TO 129000
  • Record 129001 TO 130000
  • Record 130001 TO 131000
  • Record 131001 TO 132000
  • Record 132001 TO 133000
  • Record 133001 TO 134000
  • Record 134001 TO 135000
  • Record 135001 TO 136000
  • Record 136001 TO 137000
  • Record 137001 TO 138000
  • Record 138001 TO 139000
  • Record 139001 TO 140000
  • Record 140001 TO 141000
  • Record 141001 TO 142000
  • Record 142001 TO 143000
  • Record 143001 TO 144000
  • Record 144001 TO 145000
  • Record 145001 TO 146000
  • Record 146001 TO 147000
  • Record 147001 TO 148000
  • Record 148001 TO 149000
  • Record 149001 TO 150000
  • Record 150001 TO 151000
  • Record 151001 TO 152000
  • Record 152001 TO 153000
  • Record 153001 TO 154000
  • Record 154001 TO 155000
  • Record 155001 TO 156000
  • Record 156001 TO 157000
  • Record 157001 TO 158000
  • Record 158001 TO 159000
  • Record 159001 TO 160000
  • Record 160001 TO 161000
  • Record 161001 TO 162000
  • Record 162001 TO 163000
  • Record 163001 TO 164000
  • Record 164001 TO 165000
  • Record 165001 TO 166000
  • Record 166001 TO 167000
  • Record 167001 TO 168000
  • Record 168001 TO 169000
  • Record 169001 TO 170000
  • Record 170001 TO 171000
  • Record 171001 TO 172000
  • Record 172001 TO 173000
  • Record 173001 TO 174000
  • Record 174001 TO 175000
  • Record 175001 TO 176000
  • Record 176001 TO 177000
  • Record 177001 TO 178000
  • Record 178001 TO 179000
  • Record 179001 TO 180000
  • Record 180001 TO 181000
  • Record 181001 TO 182000
  • Record 182001 TO 183000
  • Record 183001 TO 184000
  • Record 184001 TO 185000
  • Record 185001 TO 186000
  • Record 186001 TO 187000
  • Record 187001 TO 188000
  • Record 188001 TO 189000
  • Record 189001 TO 190000
  • Record 190001 TO 191000
  • Record 191001 TO 192000
  • Record 192001 TO 193000
  • Record 193001 TO 194000
  • Record 194001 TO 195000
  • Record 195001 TO 196000
  • Record 196001 TO 197000
  • Record 197001 TO 198000
  • Record 198001 TO 199000
  • Record 199001 TO 200000
  • Record 200001 TO 201000
  • Record 201001 TO 201422

  1. VACCINE POTENTIAL OF TOXOPLASMA GONDII RECOMBINANT P3

    SBC: Paravax Inc.            Topic: N/A

    N/A

    SBIR Phase I 1991 Department of Health and Human Services

  2. VACCINES DESIGNED FROM ANALYSIS OF RECENT HIV INFECTIONS

    SBC: VAXGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): An effective vaccine is the only practical way to halt the AIDS epidemic. The greatest challenge in developing an effective HIV vaccine is antigenic variation. Therefore, the present project aim is to enhance the understanding of antigenic variation by characterizing intra-subtype sequence variation among gpl20 genes from incident (new) infections, and identi ...

    SBIR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health

  3. Vaccines Designed From Analysis of Recent HIV Infections

    SBC: VAXGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): An effective vaccine is the only practical way to halt the AIDS epidemic. The greatest challenge in developing an effective HIV vaccine is antigenic variation. Therefore, the present project aim is to enhance the understanding of antigenic variation by characterizing intra-subtype sequence variation among gpl20 genes from incident (new) infections, and identi ...

    SBIR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health

  4. Vaccines for Eastern and Western Equine Encephalitis Viruses

    SBC: MAXYGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV, WEEV respectively) are arthropod-borne alphaviruses that cause periodic epizootics in the Americas. No licensed vaccines exist for these pathogens, and the experimental vaccines used under Investigational New Drug status suffer from high reactogenicity or poor immunogenicity. Vaccines aga ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health

  5. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida is a fungus that is among the most common causes of infections in hospitalized patients in the United States and worldwide. Candida spp. are one of the most common microbes that infect the blood and urine of hospitalized patients. The cost associated with Candida blood infections alone exceeds at least $1 billion per year in the US. Even with therapy, 4 ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health

  6. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida is a fungus that is among the most common causes of infections in hospitalized patients in the United States and worldwide. Candida spp. are one of the most common microbes that infect the blood and urine of hospitalized patients. The cost associated with Candida blood infections alone exceeds at least $1 billion per year in the US. Even with therapy, 4 ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health

  7. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida species are opportunistic fungal pathogens that have become among the most common causes of nosocomial infections in the United States and worldwide. Disseminated infections caused by Candida spp. have increased 15-fold in incidence in the last 15 years, and Candida is now the third most common cause of bloodstream infections. Even with modern antifunga ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health

  8. Vaccine therapy of congenital adrenal Hyperplasia

    SBC: L2 Diagnostics, LLC            Topic: N/A

    N/A

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health

  9. VACCINE TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION

    SBC: Cytel Corp.            Topic: N/A

    HEPATITIS B VIRUS (HBV) IS A HEPATOTROPIC VIRUS THAT IS A MAJOR PUBLIC HEALTH CONCERN WORLDWIDE. WHILE A RECOMBINANT SURFACE ANTIGEN VACCINE IS AVAILABLE, THERE IS NO EFFECTIVE TREATMENT FOR THE MILLIONS OF INDIVIDUALS WHO ARE CHRONICALLY INFECTED. THE OBJECTIVE IS TO DEVELOP PEPTIDE THERAPEUTICS THAT WILL GENERATE CYTOTOXIC T LYMPHOCYTES (CTL) IN VIVO AND MAY AMELEIORATE CHRONIC HBV INFECTIONS. T ...

    SBIR Phase II 1995 Department of Health and Human Services

  10. VACCINE TO TREAT CHRONIC HEPATITIS B VIRUS INFECTION

    SBC: Cytel Corp.            Topic: N/A

    N/A

    SBIR Phase I 1992 Department of Health and Human Services
US Flag An Official Website of the United States Government